Clinical Trial Update: A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder has been terminated, according to the trial record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• REL-1017

Snippet

Sponsor: Levomecor Inc. | Conditions: Major Depressive Disorder, Depression | Phase 3 | Status: TERMINATED